These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28559269)

  • 1. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
    Peloquin CA; Velásquez GE; Lecca L; Calderón RI; Coit J; Milstein M; Osso E; Jimenez J; Tintaya K; Sanchez Garavito E; Vargas Vasquez D; Mitnick CD; Davies G
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.
    Milstein M; Lecca L; Peloquin C; Mitchison D; Seung K; Pagano M; Coleman D; Osso E; Coit J; Vargas Vasquez DE; Sanchez Garavito E; Calderon R; Contreras C; Davies G; Mitnick CD
    BMC Infect Dis; 2016 Aug; 16(1):453. PubMed ID: 27567500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
    van Ingen J; Aarnoutse RE; Donald PR; Diacon AH; Dawson R; Plemper van Balen G; Gillespie SH; Boeree MJ
    Clin Infect Dis; 2011 May; 52(9):e194-9. PubMed ID: 21467012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants.
    Egelund EF; Isaza R; Brock AP; Alsultan A; An G; Peloquin CA
    J Vet Pharmacol Ther; 2015 Apr; 38(2):137-43. PubMed ID: 25236765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
    Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
    mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of standard versus high-dose rifampin for tuberculosis preventive treatment: A sub-study of the 2R
    Gafar F; Yunivita V; Fregonese F; Apriani L; Aarnoutse RE; Ruslami R; Menzies D
    Int J Antimicrob Agents; 2024 Jul; 64(1):107197. PubMed ID: 38750674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
    Aarnoutse RE; Kibiki GS; Reither K; Semvua HH; Haraka F; Mtabho CM; Mpagama SG; van den Boogaard J; Sumari-de Boer IM; Magis-Escurra C; Wattenberg M; Logger JGM; Te Brake LHM; Hoelscher M; Gillespie SH; Colbers A; Phillips PPJ; Plemper van Balen G; Boeree MJ;
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
    Acosta EP; Kendall MA; Gerber JG; Alston-Smith B; Koletar SL; Zolopa AR; Agarwala S; Child M; Bertz R; Hosey L; Haas DW
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3104-10. PubMed ID: 17576825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.
    Diacon AH; Patientia RF; Venter A; van Helden PD; Smith PJ; McIlleron H; Maritz JS; Donald PR
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2994-6. PubMed ID: 17517849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.
    Peloquin CA; Phillips PPJ; Mitnick CD; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Kaur P; Horsburgh CR
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.
    Savic RM; Ruslami R; Hibma JE; Hesseling A; Ramachandran G; Ganiem AR; Swaminathan S; McIlleron H; Gupta A; Thakur K; van Crevel R; Aarnoutse R; Dooley KE
    Clin Pharmacol Ther; 2015 Dec; 98(6):622-9. PubMed ID: 26260983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.
    Dooley KE; Savic RM; Park JG; Cramer Y; Hafner R; Hogg E; Janik J; Marzinke MA; Patterson K; Benson CA; Hovind L; Dorman SE; Haas DW;
    Antimicrob Agents Chemother; 2015; 59(6):3399-405. PubMed ID: 25824215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
    Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
    Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
    Egelund EF; Isaza R; Alsultan A; Peloquin CA
    J Zoo Wildl Med; 2016 Sep; 47(3):868-871. PubMed ID: 27691967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers.
    Healan AM; Griffiss JM; Proskin HM; O'Riordan MA; Gray WA; Salata RA; Blumer JL
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.
    te Brake LH; Ruslami R; Later-Nijland H; Mooren F; Teulen M; Apriani L; Koenderink JB; Russel FG; Burger DM; Alisjahbana B; Wieringa F; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2015; 59(6):3233-9. PubMed ID: 25801554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.
    Sturkenboom MG; Akkerman OW; van Altena R; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JC
    Eur Respir J; 2016 Oct; 48(4):1237-1239. PubMed ID: 27492836
    [No Abstract]   [Full Text] [Related]  

  • 19. Rifampin pharmacokinetics in tuberculosis-diabetes mellitus patients: a pilot study from Baja California, Mexico.
    Perea-Jacobo R; Muñiz-Salazar R; Laniado-Laborín R; Cabello-Pasini A; Zenteno-Cuevas R; Ochoa-Terán A
    Int J Tuberc Lung Dis; 2019 Sep; 23(9):1012-1016. PubMed ID: 31615609
    [No Abstract]   [Full Text] [Related]  

  • 20. Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis.
    Dian S; Yunivita V; Ganiem AR; Pramaesya T; Chaidir L; Wahyudi K; Achmad TH; Colbers A; Te Brake L; van Crevel R; Ruslami R; Aarnoutse R
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.